• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by TherapeuticsMD Inc.

    11/3/25 4:03:20 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TXMD alert in real time by email
    DEFA14A 1 ea0261240-04.htm PROXY STATEMENT

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    ________________________

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.    )

    ________________________

    Filed by the Registrant

     

    ☒

     

    Filed by a party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material under §240.14a-12

    TherapeuticsMD, Inc.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! TherapeuticsMD, Inc. Annual Meeting of Stockholders Monday, December 15, 2025 8:00 AM, Eastern Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/TXMD for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/TXMD For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/TXMD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before December 5, 2025. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On December 15, 2025 For Stockholders of Record as of October 20, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/TXMD Call: 1-866-648-8133 Email: [email protected] If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

     

    TherapeuticsMD, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 4 AND 5 THE BOARD RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR. PROPOSAL 1. To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; 1.01 Tommy G. Thompson 1.02 Cooper C. Collins 1.03 Gail K. Naughton, Ph.D. 1.04 Justin Roberts 2. To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024; 3. To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers; 4. To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025; 5. To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares; 6. To transact such other business as may properly come before the meeting or any adjournment thereof.

     

    Get the next $TXMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TXMD

    DatePrice TargetRatingAnalyst
    3/11/2022$3.00 → $2.50Buy
    HC Wainwright & Co.
    11/12/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TXMD
    SEC Filings

    View All

    SEC Form DEFA14A filed by TherapeuticsMD Inc.

    DEFA14A - TherapeuticsMD, Inc. (0000025743) (Filer)

    11/3/25 4:03:20 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by TherapeuticsMD Inc.

    DEF 14A - TherapeuticsMD, Inc. (0000025743) (Filer)

    11/3/25 4:02:02 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by TherapeuticsMD Inc.

    PRE 14A - TherapeuticsMD, Inc. (0000025743) (Filer)

    10/24/25 4:06:01 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/15/25 7:59:38 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/15/25 7:59:22 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/10/25 4:29:49 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TXMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/15/25 7:59:38 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/15/25 7:59:22 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    4/10/25 4:29:49 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TXMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $TXMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $TXMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    TherapeuticsMD Announces Second Quarter 2025 Financial Results

    TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted common share, for the second quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.

    8/12/25 4:05:00 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TherapeuticsMD Announces Full Year 2024 Financial Results

    TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended Dec

    3/27/25 4:05:00 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TherapeuticsMD Announces Third Quarter 2024 Financial Results

    TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a

    11/12/24 4:05:00 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

    HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $2.50 from $3.00 previously

    3/11/22 6:31:06 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

    HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $3.00 from $4.00 previously

    11/12/21 6:03:07 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

    6/24/21 5:13:50 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TXMD
    Leadership Updates

    Live Leadership Updates

    View All

    TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

    - Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer. The Company also announced that the Board of Directors appointed The Honorable Tommy Thompson, w

    9/12/22 6:50:00 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

    Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t

    8/8/22 8:45:00 AM ET
    $CVM
    $HSTO
    $TXMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

    - Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ:TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the appointment of Hugh O'Dowd, the Company's current President, as the Company's Chief Executive Officer and member of the board of directors. Mr. O'Dowd will succeed Robert G. Finizio, the Company's Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors. "I wan

    11/11/21 6:45:00 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TXMD
    Financials

    Live finance-specific insights

    View All

    $TXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

    - Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis

    1/3/23 6:50:00 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TherapeuticsMD Announces Third Quarter 2022 Financial Results

    - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022. "Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for IMVEXXY. Total quarterly prescriptions for both products remained relatively stable compared to the second

    11/14/22 4:05:00 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TherapeuticsMD Announces Second Quarter 2022 Financial Results

    - Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. "We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product.

    8/15/22 6:50:00 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TherapeuticsMD Inc.

    SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)

    11/12/24 4:40:08 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

    SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)

    11/17/23 9:28:51 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

    SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)

    6/30/23 8:29:16 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care